CASP2 and metabolic dysfunction-associated steatotic liver disease: Nevertheless, the current study provides compelling novel evidence that caspase-2 is a potential target to correct obesity and its associated comorbidities: metabolic syndrome, insulin resistance/T2DM and NAFLD.